Graeme Moyle

9.6k total citations
217 papers, 6.9k citations indexed

About

Graeme Moyle is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Graeme Moyle has authored 217 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Infectious Diseases, 121 papers in Virology and 90 papers in Emergency Medicine. Recurrent topics in Graeme Moyle's work include HIV/AIDS drug development and treatment (144 papers), HIV Research and Treatment (121 papers) and HIV-related health complications and treatments (90 papers). Graeme Moyle is often cited by papers focused on HIV/AIDS drug development and treatment (144 papers), HIV Research and Treatment (121 papers) and HIV-related health complications and treatments (90 papers). Graeme Moyle collaborates with scholars based in United Kingdom, United States and Italy. Graeme Moyle's co-authors include Brian Gazzard, Sundhiya Mandalia, David A. Cooper, Mark Nelson, Marta Boffito, Martin Sadler, Andrea Cossarizza, Christine Baldwin, Jaime Andrade‐Villanueva and Ploenchan Chetchotisakd and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Graeme Moyle

210 papers receiving 6.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Graeme Moyle 4.9k 3.8k 2.4k 1.5k 458 217 6.9k
Kees Brinkman 3.8k 0.8× 2.3k 0.6× 2.4k 1.0× 1.7k 1.2× 654 1.4× 139 6.0k
David A. Cooper 5.5k 1.1× 4.4k 1.2× 1.4k 0.6× 1.6k 1.1× 633 1.4× 118 7.1k
Chloe Orkin 3.8k 0.8× 2.7k 0.7× 1.8k 0.7× 1.8k 1.2× 885 1.9× 168 6.0k
Karen T. Tashima 3.7k 0.8× 2.7k 0.7× 2.0k 0.8× 983 0.7× 200 0.4× 110 5.2k
Sven A. Danner 3.6k 0.7× 3.7k 1.0× 1.2k 0.5× 1.4k 1.0× 270 0.6× 78 5.9k
Jintanat Ananworanich 4.5k 0.9× 4.2k 1.1× 1.7k 0.7× 1.8k 1.2× 134 0.3× 285 6.7k
Schlomo Staszewski 6.1k 1.2× 5.1k 1.3× 1.6k 0.6× 1.5k 1.0× 378 0.8× 115 7.3k
Antonella Castagna 3.4k 0.7× 2.5k 0.7× 886 0.4× 1.5k 1.0× 346 0.8× 340 5.7k
Marc van der Valk 2.6k 0.5× 1.9k 0.5× 1.3k 0.5× 1.6k 1.1× 1.0k 2.2× 212 4.6k
Eugènia Negredo 3.2k 0.7× 2.5k 0.7× 1.9k 0.8× 804 0.5× 171 0.4× 186 4.8k

Countries citing papers authored by Graeme Moyle

Since Specialization
Citations

This map shows the geographic impact of Graeme Moyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graeme Moyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graeme Moyle more than expected).

Fields of papers citing papers by Graeme Moyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Graeme Moyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graeme Moyle. The network helps show where Graeme Moyle may publish in the future.

Co-authorship network of co-authors of Graeme Moyle

This figure shows the co-authorship network connecting the top 25 collaborators of Graeme Moyle. A scholar is included among the top collaborators of Graeme Moyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Graeme Moyle. Graeme Moyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wohl, David A., John R. Koethe, Paul E. Sax, et al.. (2024). Antiretrovirals and Weight Change: Weighing the Evidence. Clinical Infectious Diseases. 79(4). 999–1005. 15 indexed citations
2.
Bracchi, Margherita, Nicole Pagani, Alessia Dalla Pria, et al.. (2021). A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.. PubMed. 22(5). 128–139.
3.
Scott, Whitney, James Badenoch, Joseph Chilcot, et al.. (2021). Feasibility randomized‐controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN study. European Journal of Pain. 25(7). 1493–1507. 19 indexed citations
4.
Gatell, José M., Lambert Assoumou, Graeme Moyle, et al.. (2017). Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 31(18). 2503–2514. 54 indexed citations
5.
Moyle, Graeme, Hans‐Jürgen Stellbrink, Juliet Compston, et al.. (2013). 96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study. Antiviral Therapy. 18(7). 905–913. 52 indexed citations
6.
Gallant, Joel E., Ellen Koenig, Jaime Andrade‐Villanueva, et al.. (2013). Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results. The Journal of Infectious Diseases. 208(1). 32–39. 84 indexed citations
7.
McDonald, Cheryl, Jonathan Uy, Wenhua Hu, et al.. (2012). Clinical Significance of Hyperbilirubinemia Among HIV-1–Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study. AIDS Patient Care and STDs. 26(5). 259–264. 25 indexed citations
8.
Moyle, Graeme. (2008). RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Näive HIV Patients. 46th Annual Meeting. 4 indexed citations
9.
Moyle, Graeme, José M. Gatell, Carlo Federico Perno, et al.. (2008). Potential for New Antiretrovirals to Address Unmet Needs in the Management of HIV-1 Infection. AIDS Patient Care and STDs. 22(6). 459–471. 22 indexed citations
10.
Elion, Richard, et al.. (2007). Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.. PubMed. 17(10). 484–90. 2 indexed citations
11.
Boffito, Marta, Laura Dickinson, David Back, et al.. (2006). Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses. AIDS Research and Human Retroviruses. 22(8). 749–756. 11 indexed citations
12.
Ford, Jennifer Lynn, Marta Boffito, A.D. Hill, et al.. (2006). Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. Journal of Antimicrobial Chemotherapy. 58(5). 1009–1016. 27 indexed citations
13.
Moyle, Graeme. (2005). Long-term safety and efficacy of poly-l-lactic acid in the treatment of HIV-related facial lipoatrophy. Journal of the American Academy of Dermatology. 52(3). P133–P133. 2 indexed citations
14.
Moyle, Graeme. (2005). The impact of abacavir on lipids and lipodystrophy.. PubMed. 15(2). 62–6. 4 indexed citations
15.
Moyle, Graeme. (2003). Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.. PubMed. 13(5). 223–4, 227, 244. 2 indexed citations
16.
Moyle, Graeme. (2002). Overcoming Obstacles to the Success of Protease Inhibitors in Highly Active Antiretroviral Therapy Regimens. AIDS Patient Care and STDs. 16(12). 585–597. 14 indexed citations
17.
Moyle, Graeme & Carol M. Baldwin. (2000). Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution.. PubMed. 10(8). 479–85. 13 indexed citations
18.
Moyle, Graeme. (2000). Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection. Current Opinion in Infectious Diseases. 13(1). 19–25. 8 indexed citations
19.
Sullivan, Ann, Mark Nelson, Andrew J Shaw, et al.. (2000). Efficacy of a Nelfinavir- and Nevirapine-Containing Salvage Regimen. HIV Clinical Trials. 1(1). 7–12. 7 indexed citations
20.
Gazzard, Brian & Graeme Moyle. (1999). Commentary: resistance testing--a clinical perspective.. Sexually Transmitted Infections. 75(3). 141–2. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kees Brinkman Breakdown of academic impact, for papers by David A. Cooper Breakdown of academic impact, for papers by Chloe Orkin Breakdown of academic impact, for papers by Karen T. Tashima Breakdown of academic impact, for papers by Sven A. Danner Breakdown of academic impact, for papers by Jintanat Ananworanich Breakdown of academic impact, for papers by Schlomo Staszewski Breakdown of academic impact, for papers by Antonella Castagna Breakdown of academic impact, for papers by Marc van der Valk Breakdown of academic impact, for papers by Eugènia Negredo
Rankless by CCL
2026